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Introduction
Hypertension is a chronic condition that affects about 1 billion 
people and is the number one risk factor for premature death 
worldwide [1]. It is associated with an increased risk of heart attack, 
stroke, heart failure, kidney disease and death [1-3]. Several guidelines 
for the pharmacological management of hypertension depending 
on the severity of the disease have been published [4-8]. Different 
classes of antihypertensive drugs used to treat hypertension are 
recommended including angiotensin-converting enzyme (ACE) 
inhibitors, angiotensin receptor blockers (ARBs), diuretics, beta-
blockers, calcium channel blockers (CCBs) and others depending on 
the cause of hypertension. These drugs are used as monotherapy or 
in combination. American and international guidelines acknowledge 
that most patients need combination therapy to achieve blood pressure 
(BP) goals. Advantages of combinations over monotherapy in the 
treatment of hypertension include: faster achievement of target BP, 
greater efficacy, higher response rates, improved outcomes, increased 
potential for end organ protection, potential for fewer side effects, 
simple convenient regimen, improved compliance and lower treatment 
costs [9,10]. Among combination regimens are the ARBs with CCBs 
which lead to synergistic BP reduction and to complementary clinical 
benefits [10-13]. Inhibition of the RAAS system is usually required to 
get the most effective BP lowering with combination therapy; CCBs are 
vasodilators and can activate the RAAS which limits their effectiveness; 
reflex activation of the sympathetic nervous system by CCB-induced 
vasodilatation is diminished by ARBs; ARBs decrease the adverse 
effects associated with CCBs (e.g. peripheral edema). ARBs and CCBs 
are therefore recommended for complementary indications. ARBs 
confer stroke protection, cardiac protection, renal protection, and 
tolerability similar to placebo, without dose-related symptomatic and 
metabolic adverse events. CCBs are beneficial in reducing stroke and 
treating angina and cardiac ischemia. 
The combination of an ARB with a CCB as a single pill, fixed dose 
treatment is emerging as possibly the best therapy for preventing 
cardiovascular disease. It is important to highlight that some benefits 
conferred by ARBs may not be class effects but rather molecular effects. 
Losartan, the first FDA approved ARB, is the most extensively studied 
ARB and has more approved indications as compared to other ARBs 
[14]. In addition, losartan is devoid of dry cough and angioedema as 
compared to its ACE-inhibiting counterparts.
Losartan and its principal active metabolite (EXP3174) block 
the AT1 receptor which mediates vasoconstriction and aldosterone-
secretion, leading to vasodilation and decrease sodium and water 
retention [15]. According to the Biopharmaceutics classification 
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system [16], losartan is a Class 3 drug as it exhibits a high solubility 
and low permeability [17]. It is a well absorbed orally active agent that 
undergoes substantial first-pass metabolism by CYP450 enzymes with 
a systemic bioavailability of approximately 33%. It is converted, in part, 
to an active 5-carboxylic acid metabolite which is 10 to 40 times more 
potent than losartan (by weight) and appears to be a reversible, non-
competitive inhibitor of the AT1 receptor. While maximum plasma 
concentrations of losartan and its active metabolite are approximately 
equal, the AUC of the metabolite is about 4 times as great as that of 
losartan. Food slows absorption of losartan and decreases its peak 
plasma concentration but has minimal effect on AUC of losartan 
or its active metabolite. Following oral administration of a single 
dose of losartan, about 4% of the dose is excreted unchanged in the 
urine and about 6% is excreted in urine as active metabolite. Biliary 
excretion contributes to the elimination of both parent drug and active 
metabolite. The pharmacokinetics of losartan and EXP3174 are linear 
with oral losartan doses up to 200 mg and neither one accumulate in 
plasma upon repeated once-daily dosing [14,18].
Amlodipine is a calcium ion influx inhibitor of the dihydropyridine 
group (slow channel blocker or calcium ion antagonist). The 
mechanism of the antihypertensive action of amlodipine is due to a 
direct relaxant effect on vascular smooth muscle. Amlodipine dilates 
peripheral arterioles and veins thus, reduces the total peripheral 
resistance (afterload and preload). Since the heart rate remains stable, 
this unloading of the heart reduces myocardial energy consumption 
and oxygen demand. Another mechanism of action of amlodipine 
involves dilatation of coronary arteries, increasing oxygen supply, both 
in normal and ischemic regions [19].
According to the Biopharmaceutics Classification System, 
amlodipine is a Class 1 drug as it exhibits high solubility and high 
permeability [17]. After oral administration of therapeutic doses, 
amlodipine is well absorbed. Absolute bioavailability has been 
estimated to be between 64 and 90% and is not altered by food intake. It 
is extensively converted to inactive metabolites in the liver (about 90%) 
with 10% of the parent compound and 60% of the metabolites undergo 
renal excretion. Pharmacokinetic parameters are not significantly 
influenced by renal impairment [20,21].
This bioequivalence study was performed using an in vivo method 
where the concentrations of the active ingredient and metabolite in an 
accessible biological fluid are measured as a function of time in humans. 
According to EMA, this is the most recommended method to assure that 
formulations perform in an equivalent manner and thus demonstrate 
that they are therapeutic equivalent [22]. This bioequivalence study was 
performed on the highest strength available. The medicine is available 
in two strengths: losartan potassium 100 mg/amlodipine (as besylate) 
10 mg tablets and losartan potassium 100 mg/amlodipine (as besylate) 
5 mg tablets.
Inter-subject pharmacokinetic variability for amlodipine and 
losartan is about 14.7% and 42.5% respectively. Multiple dose 
pharmacokinetics are predictable from single-dose data, [18,21].
Objectives
This study was conducted to assess the bioequivalence of a new fixed 
dose combination (FDC) including losartan potassium and amlodipine 
besylate (Losanet AM, Pharmaline, Lebanon) with coadministration 
of losartan potassium and amlodipine besylate as separate tablets, 
(respectively Cozaar 100 mg, Merck Sharp & Dohme Ltd, UK and 
Norvasc 10 mg, Pfizer, Canada). The study protocol was prepared with 
relevance to the requirements set in the EMA CPMP (CPMP/EWP/
QWP/1401/98 Rev 1 [22] guidance for conduction of bioequivalence 
studies.
Materials and Methods
Study products
Investigational product: Losanet AM – Losartan potassium 100 mg 
and Amlodipine (as besylate) 10 mg tablets 
Batch no.: LABE2011 Expiry Date: October/2013
Manufacturer: Pharmaline, Lebanon
Reference product: Cozaar - Losartan potassium 100 mg tablets
Batch no.: NP03390 Expiry Date: October/2013
Manufacturer: MSD, UK
Reference product: Norvasc - Amlodipine as besylate 10 mg tablets
Batch no.: A10469532 Expiry Date: August/2014
Manufacturer: Pfizer, Canada
Study design
Forty two healthy, Caucasian adult males participated in this 
comparative study at PRU, Amman, Jordan. Although the study 
targeted, as per the protocol inclusion criteria, the general population, 
no female showed up at the site. The sample size calculation was based 
on 40% intra-subject variability of Cmax and 80% power to detect 20% 
difference between the two formulations [18, 21, 23, 24]. The mean age 
was 28 ± 8 years with a range of 18 to 48 years old, mean body weight 
was 77 ± 10 kg with a range of 58-102 kg, mean body height was 176 ± 6 
cm with a range of 164-192 cm and body mass index was 25.1 ± 2.1 kg/
m2 with a range of 21.3-30.0 kg/m2. The volunteers had medical history 
and physical examination within the range of clinical acceptability, and 
laboratory results (hematology, blood biochemistry, and urine analysis) 
within normal ranges. All subjects were instructed to abstain from 
taking any drug including vitamins and herbal supplements for 14 days 
prior to first dosing and during the study period. They were informed 
about the aim and risks of the study by the clinical investigator and then 
signed a written informed consent statement before entering the study. 
The study was carried out in accordance with the principles enunciated 
in the Declaration of Helsinki resolved in Helsinki in 1964 and amended 
in Seoul, 2008 [25], the ICH harmonized tripartite guideline regarding 
Good Clinical Practice [26], OECD Principles of Good Laboratory 
practices [27] and the local requirements of the Jordan Food and 
Drug Administration in relation to human rights and confidentiality 
[28]. Before the start of the study, the protocol was approved by the 
Institutional Review Board (IRB) of PRU, Amman, Jordan.
Drug administration and sample collection
The study was designed as an open-label, randomized, single dose, 
two-treatment, three-sequence, three-period, and crossover design 
performed under fasting conditions. The study flow chart (Figure 1) 
summarizes the study procedure.
Each period lasted 168 hours. The three periods were separated 
from each other by a washout period of 21 days. Subjects were admitted 
to PRU clinical site approximately 12 hours prior to study drug 
administration, until 24 hours after dosing in each period. The subjects 
returned to the site to give the 36.00 hour and remaining samples as per 
schedules time. Following an overnight fasting of at least 10 hours, the 
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Merck (Germany). Losartan potassium was obtained from Pharmaline 
whereas the internal standard was from TRC (Canada).
The LC-MS-MS consisted of liquid chromatographic system 
(Agilent 1200 infinity, USA) , coupled with a triple quadrupole 
spectrometer (API 4000) from Applied Biosystems, (MDS Sciex, 
Canada), equipped with ESI source for the ionization (positive 
ionization mode). Integration was done using the Analyst 1.5.2 software 
(Applied Biosystems). 
Chromatographic separation for Losartan was performed using 
Phenomenex Luna C18 (3 μm) (50 × 3.00 mm) column from GL 
sciences, Japan. The mobile phase consisted of acetonitrile, water mixture 
(60:40) with 0.05% FA and eluted at a rate of 0.500 (mL/min) with 
splitter (2/3) out for losartan. A flushing solution including acetonitrile, 
water, 2-propanol and FA mixture (30:40:30:0.05) was used. The auto-
sampler temperature was 15°C whereas the column temperature 
was 30°C. Detection was done by multi reaction monitoring (MRM) 
mode, using the positive mode. The ion transition (m/z) for losartan 
was: 423.140/207.100. The ion transition for the internal standard 
(Losartan-d4) was: 427.199/211.100. The ion transition (m/z) for LCA 
was: 437.063/235.100. The ion transition for the internal standard 
(LCA-d4) was: 441.107/239.200. The peak area was measured, and the 
peak area ratio of drug to internal standard and the concentration were 
calculated by Analyst software. 
Method development and validation were conducted in accordance 
with international guideline [29]. Under the described conditions, 
the lower limit of quantitation from 200 µl plasma was 2.929 ng/
ml for losartan and 3.469 ng/ml for LCA. Linearity was evaluated 
by calculating the linear regression (product moment correlation 
coefficient, r), and by evaluating the back calculated concentrations of 
the calibration standards. Results of the calibration curve linearity are 
summarized in Table 1a and Table 1b. 
The relationship between concentration and peak area ratio was 
found to be linear within the range of 2.929-761.605 ng/ml and 3.469 
– 901.966 ng/ml for losartan and for LCA respectively. Accuracy and 
precision were verified using quality control samples at low, medium, 
high concentration as well as at the LLOQ. Results are reported in Table 
1a, and Table 1b.
study subjects were given single dose of either formulations (reference 
or test) of losartan potassium 100 mg and amlodipine as besylate 10 
mg with 240 ml of water. No food was allowed until 4 h after dose 
administration. Lunch and dinner were given to all volunteers according 
to a time schedule; breakfast was served after the 24 hours sample was 
collected. Water intake was allowed one hour after the dosing; there was 
no restriction on water intake 4 hours after drug administration. The 
volunteers were continuously monitored throughout the confinement 
period of study. They were not permitted to lie down or sleep for the 
first six hours after the dose. Blood samples were collected in each 
study period before (1.00 hour pre-dose) and at 0.25, 0.50, 1.00, 1.33, 
1.66, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 6.00, 7.00, 8.00, 9.00, 10.00, 11.00, 
12.00, 16.00, 24.00, 36.00, 48.00, 72.00, 144.00 and 168.00 hours after 
dosing. For each sample, 8 ml of blood for losartan and amlodipine 
assay were drawn into heparinated tubes through indwelling cannula. 
Blood samples were centrifuged at 4000 rpm for 5 minutes. The 
resulting plasma was immediately stored at -70°C until assayed. After a 
washout period of 21 days the study was repeated in the same manner 
to complete the crossover design.
Analysis for parent drugs
Losartan and its metabolite: Although bioequivalence acceptance 
criteria were only based on parent compound pharmacokinetic 
parameters, assessing losartan metabolite data was done as supportive 
evidence of comparable therapeutic outcome. Losartan, losartan 
carboxylic acid (LCA) and the internal standards (Losartan-d4 and 
Losartan-d4 carboxylic acid (LCA-d4)) were extracted from human 
plasma samples by protein precipitation using acetonitrile. Fifty 
microliters of each internal standard working solution (1.682 µg /mL 
and 1.656 µg /mL respectively) were added to 0.200 ml of plasma sample 
and vortexed for 30s. Then 1 mL acetonitrile was added to the sample 
which was subjected to vortex for 30 seconds followed by decantation 
of the supernatant layer. Ten microliters were injected to the column. 
Analysis was performed using a method fully developed and 
validated at PRU Bio-analytical laboratory. The study plasma samples 
were analyzed using a validated LC coupled with MS-MS detector. 
All solvents used were of HPLC grade. Acetonitrile and Methanol 
were purchased from Honywell (USA). Iso propanol was purchased 
from Carbon Group (USA). Formic Acid (FA) was purchased from 
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Figure 1: Study Flow Chart.
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The intra-day accuracy of the method for losartan ranged from 91.40 
to 103.08%, while the intra-day precision ranged from 2.35 to 7.55%. 
The inter-day accuracy for losartan ranged from 95.73 to 105.61% while 
the inter-day precision ranged from 3.64 to 6.56%. Absolute recovery - 
percentage ratio of the concentrations in an extracted plasma sample 
with the reference sample of the same concentration which was 
dissolved in the same solution as extracted sample - was between 111.70 
and 115.87% for losartan and 100.83% for losartan internal standard. 
For LCA, absolute recovery was between 97.10 and 108.55% and for 
LCA-d4 135.75%. Accuracy ranged between 100.13% and 107.69%. 
Short-term temperature stability study demonstrates that losartan and 
losartan carboxylic acid metabolite are stable in plasma for 24 hours 
on the bench at room temperature, as shown in Table 1a and in Table 
1b. In addition, long term stability studies showed that losartan and 
losartan carboxylic acid metabolite in the plasma samples were stable 
when stored frozen for 32 days at both freezer of temperature range 
between -80°C to -60°C as well as between -25°C to -15°C. Freeze and 
thaw stability test was determined after four cycles: after storage at 
temperature range of -80°C to -60°C and -25°C to -15°C for at least 12 
hours (or 24 hours for the first cycle), samples were completely thawed 
unassisted at room temperature. The stability results indicate that 
losartan and losartan carboxylic acid metabolite are stable under fifth 
freezing and thawing cycles at both temperature ranges. Table 1a and 
table 1b report the results after storage at temperature range of -80°C 
to -60°C.
Amlodipine: Amlodipine and the internal standard 
(Amlodipine-d4 maleic acid salt) were extracted from human plasma 
samples by liquid-liquid extraction using a mixture (70:30) of diethyl 
ether (DEE) and dichloromethane (DCM). Fifty microliters of internal 
standard Amlodipine d-4 working solution (77.662 ng /mL) were 
added to 0.500 ml of plasma sample and vortexed for 30s. Then 4.00mL 
(DEE: DCM) (7:3) were added followed by sample shaking for 20 
minutes after which samples are centrifuged for 10 minutes at 4000 
rpm. Samples were then evaportated under steam of nitrogen at 40˚C 
and then reconstituted with 150 µL mobile phase. Twenty microliters 
were injected to the column.
Analysis was performed using a method fully developed and 
validated at PRU Bio-analytical laboratory. The study plasma samples 
were analyzed for amlodipine using a validated LC coupled with 
MS-MS detector (API4000). All solvents used were of HPLC grade; 
Acetonitrile was purchased from Honywell (USA). Methanol and Iso 
propanol was purchased from Carbon Group (USA). Ammonium 
acetate was purchased from Merck (Germany). Diethyl ether was 
purchased from JHD (India). Dichloromethane was purchased from 
Pharmco (USA). Amlodipine was obtained from Pharmaline whereas 
the internal standard Amlodipine-d4 Maleic Acid Salt was from TRC 
(Canada). 
The LC-MS-MS was consisted of liquid chromatographic system 
(Agilent 1200 infinity, USA) , coupled with a triple quadrupole 
spectrometer (API 4000) from Applied Biosystems, (MDS Sciex, 
Canada), equipped with ESI source for the ionization (positive 
ionization mode). Integration was done using the Analyst 1.5.2 software 
(Applied Biosystems).
Chromatographic separation was performed using Agilent 
XDB C18 (5 μm) (150 × 4.6 mm) column from GL sciences, Japan.   
Table 1: Linearity, accuracy, precision and stability data for the analytical method validation for the determination of losartan (1a), LCA (1b) and amlodipine (1c) in plasma
Regression equation Concentration range (ng/ml) Number of points Correlation coefficient Precision (%)
2.929-761.605 8 0.9990 6.38%
Plasma sample 2.929 ng/ml 8.788 ng/ml 380.803 ng/ml 571.204 ng/ml
Accuracy (%) Precision (%) Accuracy (%) Precision (%) Accuracy (%) Precision (%) Accuracy (%) Precision (%)
Intra-batch (n=6) 91.40 3.92 95.38 7.55 102.57 3.18 103.08 2.35
Inter-batch (n=12) 95.73 6.56 96.46 6.03 102.08 3.64 105.61 5.43
Short-term stability (n=6) - - 97.64 2.42 - - 95.24 2.27
Freeze and thaw stability (n=6) - - 101.93 3.71 - - 103.42 2.35
a
b
Regression equation Concentration range (ng/ml) Number of points Correlation coefficient Precision (%)
3.469-901.966 8 0.9988 3.44%
Plasma sample 3.469 ng/ml 10.398 ng/ml 450.583 ng/ml 675.874 ng/ml
Accuracy (%) Precision (%) Accuracy (%) Precision (%) Accuracy (%) Precision (%) Accuracy (%) Precision (%)
Intra-batch (n=6) 97.61 8.21 100.71 3.02 106.51 2.22 104.81 1.21
Inter-batch (n=12) 103.57 9.32 100.13 4.35 105.80 3.36 107.69 4.88
Short-term stability (n=6) - - 94.94 3.72 - - 99.39 0.98
Freeze and thaw stability (n=6) - - 93.59 5.64 - - 106.71 1.97
c
Regression equation Concentration range (ng/ml) Number of points Correlation coefficient Precision (%)
0.118-9.447 8 0.9967 13.86%
Plasma sample 0.118 ng/ml 0.354 ng/ml 4.724 ng/ml 7.085 ng/ml
Accuracy (%) Precision (%) Accuracy (%) Precision (%) Accuracy (%) Precision (%) Accuracy (%) Precision (%)
Intra-batch (n=6) 94.07 12.61 97.46 8.99 110.99 2.82 104.26 2.29
Inter-batch (n=18) 100.85 15.13 98.02 9.80 107.11 6.80 99.65 4.87
Short-term stability (n=6) - - 108.19 9.66 - - 95.62 1.93
Freeze and thaw stability (n=6) - - 98.02 14.12 - - 99.53 1.36
Citation: Bustami R, Khasawneh S, Absi W, Feddah H, Mroueh M, et al. (2015) Bioequivalence of Losartan/Amlodipine Fixed Dose Combination 
Tablets (Losanet AM) Compared with Concomitant Administration of Single Components of Losartan and Amlodipine Tablets in Healthy 
Human Volunteers. J Bioequiv Availab 7: 216-224. doi:10.4172/jbb.1000243
J Bioequiv Availab
ISSN: 0975-0851 JBB, an open access journal Volume 7(5): 216-224 (2015) - 220 
The mobile phase consisted of acetonitrile, methanol and 0.008 
M ammonium acetate mixture (50:30:20) and eluted at a rate of 
1.00(mL/min). Detection was done by multi reaction monitoring 
(MRM) mode, using the positive mode. The ion transition (m/z) for 
amlodipine was: 409.100/238.100. The ion transition for the internal 
standard (amlodipine-d4) was: 413.158/238.000. The peak area was 
measured, and the peak area ratio of drug to internal standard and the 
concentration were calculated by Analyst software.
Method development and validation were conducted in accordance 
with international guideline [29]. Under the described conditions, the 
lower limit of quantitation from 500 µl plasma was 0.118 ng/ml for 
amlodipine. Linearity was evaluated by calculating the linear regression 
(product moment correlation coefficient, r), and by evaluating the back 
calculated concentrations of the calibration standards. Results of the 
calibration curve linearity are summarized in Table 1c. 
The relationship between concentration and peak area ratio was 
found to be linear within the range of 0.118-9.447 ng/ml. Accuracy and 
precision were verified using quality control samples at low, medium, 
high concentration as well as at the LLOQ. Results are reported in Table 1c.
The intra-day accuracy of the method for amlodipine ranged 
from 94.07 to 110.99%, while the intra-day precision ranged from 
2.29 to 12.61%. The inter-day accuracy for amlodipine ranged from 
98.02 to 107.11% while the inter-day precision ranged from 4.87 to 
15.13 %. Absolute recovery - percentage ratio of the concentrations 
in an extracted plasma sample with the reference sample of the same 
concentration which was dissolved in the same solution as extracted 
sample was between 93.24 and 103.40% for amlodipine and 106.92% 
for the internal standard. Short-term temperature stability study 
demonstrates that amlodipine in plasma is stable for 24 hours on the 
bench at room temperature, as shown in Table 1c. In addition, long-
term stability studies showed that amlodipine in plasma samples was 
stable when stored frozen for 131 days at both freezer of temperature 
range between -80°C to -60°C as well as between -25°C to -15°C. Freeze 
and thaw stability test was determined after five cycles: after storage 
at temperature range of -80°C to -60°C and -25°C to -15°C for at least 
12 hours (or 24 hours for the first cycle), samples were completely 
thawed unassisted at room temperature. The stability results indicate 
that amlodipine is stable under fifth freezing and thawing cycles at 
both temperature ranges. Table 1c reports the results after storage at 
temperature range of -80°C to -60°C.
Pharmacokinetic analysis
Pharmacokinetic analysis was performed using the WinNonlin® 
Computer Program Version 5.3 (Pharsight, USA). The elimination rate 
constant (λz) was obtained as the slope of the linear regression of the 
log-transformed concentration values versus time data in the terminal 
phase. Elimination half-life (T1/2) was calculated as 0.693/ λz. Area 
under the plasma concentration versus time curve (AUC0-t), from time 
(0) to the last measurable concentration (t), was calculated by the linear 
trapezoidal method. The area under the plasma concentration versus 
time curve from time (0) to infinity (AUC0-∞) is calculated as the sum of 
the AUC0-t plus the ratio of the last measurable plasma concentration to 
the elimination rate constant. The residual area was determined as the 
ratio of the difference in the two areas under the plasma concentration 
versus time curve over AUC0-∞. The mean residual time from zero to 
infinity is calculated from the ratio of the area under the first moment 
curve to area under the plasma concentration versus time curve.
Statistical analysis
The pharmacokinetic parameters AUC0-t, AUC0-∞ and Cmax were 
considered as primary variables. Two-way analysis of variance for 
crossover design was used to assess the effect of formulations, periods, 
sequences and subjects on these parameters. Difference between two 
related parameters was considered to be statistically significant for 
p-value equal to or less than 0.05. Parametric 90% confidence intervals 
based on the ANOVA of the mean test / reference (T/R) ratios of 
AUCs and Cmax were computed, [30]. The data was transformed prior 
to analysis using a logarithmic transformation. Tmax adopted a non-
parametric and was applied to untransformed data.
Results and Discussion
Out of the forty two volunteers, forty subjects completed the study. 
One subject was excluded by clinical investigator due to fever, cough, 
sore throat and headache before dosing of period III. Before admission 
in period II, another subject was withdrawn from the study due to 
positive drug abuse (benzodiazepines). Samples for all the subjects who 
completed the clinical part of the study were analyzed and included in 
the pharmacokinetic analysis and bioequivalence assessment. Losartan 
and amlodipine were well tolerated; unexpected incidents that could 
have influenced the outcome of the study did not occur. All volunteers 
were discharged in good health.
Both formulations were readily absorbed from the gastrointestinal 
tract: first quantifiable plasma concentrations of amlodipine and 
losartan were observed at 0.25 hour; and at 0.50 hour for LCA. 
Amlodipine and losartan were measurable at least at 1.0 hour in all 
volunteers. The mean-concentration-time profiles for losartan, LCA 
and amlodipine for the two formulations are shown in Figures 2-4. 
Means of peak concentration of 462.247 and 431.910 ng/ml for losartan 
were attained at means of 1.11 and 1.31 hour after drug administration 
and then declined rapidly. No losartan was detectable at 48 hours for 
most volunteers. Losartan concentrations were quantifiable to 144.00 
hours in 1 subject after the test product administration and in 1 subject 
at 72.00 hours after the reference product administration.
Means of peak concentration of 602.092 and 632.874 ng/ml for 
LCA metabolite were attained at means of 3.27 and 3.34 hour after 
drug administration and then declined gradually. No carboxylic acid 
losartan metabolite was detectable after 144 hours.
Means of peak concentration of 6.167 and 5.914 ng/ml for 
amlodipine were attained at means of 6.14 and 6.52 hour after drug 
administration and then declined gradually. Amlodipine was still 
detectable at 168 hours.
Tables 2a, 2b and 2c report the pharmacokinetic parameters of 
losartan, LCA metabolite and amlodipine for the two brands which 
highlights the closeness of the results. Mean and standard deviation of 
the three pharmacokinetic parameters of the two formulations did not 
differ significantly. 
More variability in Cmax is expected as measurement relies on one 
single point and not on several points as with the area under the curve. 
For losartan, the relative bioavailability of Losanet AM on the basis of 
Cozaar is 883.184 ± 556.879% for AUC0-t, 865.997 ± 419.871% for AUC0-
∞, and 431.910 ± 259.093% for Cmax. For LCA, the relative bioavailability 
of Losanet AM on the basis of Cozaar is 4032.223 ± 1991.174% for 
AUC0-t, 4100.329 ± 2014.905% for AUC0-∞, and 632.874 ± 353.512% for 
Cmax. Data on LCA metabolite was used as supportive data only. For 
amlodipine, the relative bioavailability of Losanet AM on the basis of 
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Norvasc is 311.535 ± 106.136% for AUC0-t, 353.515 ± 123.080% for 
AUC0-∞, and 5.914 ± 1.329% for Cmax. For bioequivalence assessment, 
the test & reference products are considered bioequivalent if the 90% 
confidence interval of the geometric mean of the log-transformed data 
of the test/reference ratio percentage for amlodipine and for losartan 
fall within 80.00-125.00 % for each of the primary end points. As 
reported in Table 3a, 3b and 3c, confidence intervals for amlodipine 
primary pharmacokinetic parameters Cmax, AUC0-t and AUC0-∞ were 
99.31-107.04%, 100.83-110.94% and 101.25-109.21% respectively. For 
losartan, Cmax, AUC0-t and AUC0-∞ values were 87.77-114.60%, 88.61-
101.04% and 91.21-102.55% respectively. For LCA metabolite, Cmax, 
AUC0-t and AUC0-∞ values were 88.62-100.30%, 92.26-99.01% and 
93.30-99.89% respectively. All values were within the accepted 80-125% 
range. Analysis of variance (ANOVA) for these parameters, after log-
transformation of the data, reveals no statistically significant difference 
between the two formulations, with p-value greater than 0.05. ANOVA 
analysis of the drug demonstrates that the sequence, product and period 
effect for all bioequivalence metrics did not influence the outcome of 
the study. 
700
600
500
400
300
200
100
0
0            20           40            60           80          100         120          140        160          180
Time (hr)
LOSANET AM
COZAAR
P
la
sm
a 
Lo
as
rta
n 
G
eo
m
et
ric
_m
ea
n 
C
on
ce
nt
ra
tio
n 
(n
g/
m
l)
Figure 2: Geometric mean (SD) plasma concentration-time profiles for losartan following administration of FDC tablets (Losanet AM) and 
coadministration of losartan (Cozaar) and amlodipine individual tablets to 40 healthy human volunteers. 
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Figure 3: Geometric mean (SD) plasma concentration-time profiles for LCA following administration of FDC tablets (Losanet AM) and coadministration 
of losartan (Cozaar) and amlodipine individual tablets to 40 healthy human volunteers.
Citation: Bustami R, Khasawneh S, Absi W, Feddah H, Mroueh M, et al. (2015) Bioequivalence of Losartan/Amlodipine Fixed Dose Combination 
Tablets (Losanet AM) Compared with Concomitant Administration of Single Components of Losartan and Amlodipine Tablets in Healthy 
Human Volunteers. J Bioequiv Availab 7: 216-224. doi:10.4172/jbb.1000243
J Bioequiv Availab
ISSN: 0975-0851 JBB, an open access journal Volume 7(5): 216-224 (2015) - 222 
P
la
sm
a 
A
m
lo
di
pi
ne
 G
eo
m
et
ric
_M
ea
n 
C
on
ce
nt
ra
tio
n 
(n
g/
m
l)
8
6
4
2
0
0             20            40           60            80            100         120          140          160          180
LOSANET  AM
NORVASC
Time (hr)
Figure 4: Geometric mean (SD) plasma concentration-time profiles for amlodipine following administration of FDC tablets (Losanet AM) and 
coadministration of losartan and amlodipine (Norvasc) individual tablets to 40 healthy human volunteers.
a
Pharmacokinetic 
Parameter
Losanet AM 100/10 mg
tablets (Test)
Cozaar 100 mg
tablets (Reference)
Cmax (ng /ml) 462.247 ± 332.039 431.910 ± 259.093
AUC 0-t (ng*hr/ml) 824.602 ± 404.889 883.184 ± 556.879
AUC 0-∞ (ng*hr/ml) 854.606 ± 450.241 865.997 ± 419.871
Tmax (hr) 1.11 ± 0.81 1.31 ± 0.86
T1/2 (hr) 3.82 ± 10.16 2.47 ± 1.19
Kelimination (hr-1) 0.3118 ± 0.0949 0.3199 ± 0.0893
MRTinf (hr) 5.28 ± 16.04 3.38 ± 1.42
Residual area (%) 2.599 ± 4.582 2.212 ± 2.756
b
Table 2: Pharmacokinetic parameters of losartan (2a), LCA (2b) and amlodipine 
(2c) for two brands (mean ± standard deviation, n=40)
Pharmacokinetic 
Parameter
Losanet AM 100/10 mg
tablets (Test)
Cozaar 100 mg
tablets (Reference)
Cmax (ng /ml) 602.092 ± 327.098 632.874 ± 353.512
AUC 0-t (ng*hr/ml) 3911.388 ± 1780.929 4032.223 ± 1991.174
AUC 0-∞ (ng*hr/ml) 4002.867 ± 1820.782 4100.329 ± 2014.905
Tmax (hr) 3.27 ± 1.27 3.34 ± 1.26
T1/2 (hr) 8.72 ± 7.76 7.02 ± 3.19
Kelimination (hr-1) 0.1046 ± 0.0364 0.1096 ± 0.0295
MRTinf (hr) 10.64 ± 7.99 9.09 ± 2.43
Residual area (%) 2.958 ± 4.876 2.486 ± 3.741
c
Pharmacokinetic 
Parameter
Losanet AM 100/10 mg
tablets (Test)
Norvasc 10 mg
tablets (Reference)
Cmax (ng /ml) 6.167 ±1.382 5.914 ±1.329
AUC 0-t (ng*hr/ml) 327.518 ±96.181 311.535 ±106.136
AUC 0-∞ (ng*hr/ml) 370.380 ±114.175 353.515 ±123.080
Tmax (hr) 6.14 ±1.86 6.52 ±1.99
T1/2 (hr) 51.29 ±10.77 51.24 ±10.66
Kelimination (hr-1) 0.0141 ±0.0028 0.0141 ±0.0031
MRTinf (hr) 72.69 ±14.67 72.18 ±14.76
Residual area (%) 11.129 ± 4.745 11.806 ±7.579
The bioequivalence of Losanet AM 100/10 tablets vs 
coadministration of Cozaar® and Norvasc tablets following a single 
dose administration of 100 mg losartan and 10 mg amlodipine to 
healthy adults under fast conditions was demonstrated.
The administration of losartan with amlodipine is common in 
medical practice. Such combination proved to be effective and safe 
[31-35] especially that amlodipine-induced edema with associated 
activation of the RAAS is attenuated by losartan. The LOTHAR study 
[31] evaluated medium and long term (one year) efficacy, tolerability 
and metabolic effects of the FDC of amlodipine and losartan compared 
to amlodipine or losartan alone. The clinical trial was performed 
with 198 patients in stage 1 and 2 essential hypertension. The fixed 
Table 3: Statistical Analysis: 90% confidence intervals of log transformed data of 
losartan (3a), LCA (3b) and amlodipine (3c), n=40.
a
Assessment Parameter Cmax AUC0-t AUC0-∞
Point Estimate (%) 100.29 94.62 96.71
Lower limit (%) 87.77 88.61 91.21
Upper limit (%) 114.60 101.04 102.55
Power 73.56   99.98 99.50
b
Assessment Parameter Cmax AUC0-t AUC0-∞
Point Estimate (%) 94.28 95.57 95.64
Lower limit (%) 88.62 92.26 93.30
Upper limit (%) 100.30 99.01 99.89
Power 99.68 100.00 100.00  
c
Assessment Parameter Cmax AUC0-t AUC0-∞
Point Estimate (%) 103.10 105.76 105.16
Lower limit (%) 99.31 100.83 101.25
Upper limit (%) 107.04 110.94 109.21
Power 100.00 100.00 99.99
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combination was associated with a high antihypertensive efficacy that is 
sustained in the long term and a low frequency of adverse events. Long-
term incidence of leg edema was approximately four-fold lower than 
that observed with amlodipine alone. The fixed combination did not 
change glucose and lipid metabolism in the medium or in the long term. 
Another study [32] compared the blood-pressure lowering efficacy of 
amlodipine and losartan combination with amlodipine monotherapy 
after 6 weeks of treatment. The result demonstrates that the amlodipine 
/losartan combination provides an effective and generally well-tolerated 
first line therapy for reducing blood pressure in stage 2 hypertensive 
patients. In addition, a clinical trial [33] was conducted with 320 
patients with essential hypertension dosed with either the fixed dose 
combination or with mono-agent (amlodipine or losartan) for 8 weeks. 
The study demonstrates that depending on the dose, the FDC resulted 
in similar BP lowering or significantly greater BP lowering compared 
with amlodipine or losartan monotherapy, and was determined to be 
safe and tolerable in this patient population. Evaluation of the efficacy 
and safety profiles of the FDC was also demonstrated in patients with 
essential hypertension inadequately controlled on losartan100 mg [34]. 
Switching to the FDC therapy was associated with significantly greater 
reductions in BP and superior achievement of BP goals compared 
with a maintenance dose of losartan 100 mg in this population. Both 
treatments were well tolerated with comparable safety profiles.
The clinical data on the fixed dose combination of losartan and 
amlodipine demonstrates that it is associated with a faster achievement 
of BP goal and greater reductions in BP as well as higher BP response 
and control rates compared with monotherapy, reduced adverse events 
and improved patience compliance. The combination is a rational and 
convenient option in patients who are likely to need multiple drugs to 
achieve target blood pressure (stage II HTN, diabetes, chronic kidney 
disease, or cardiovascular disease). Due to its metabolic neutrality, the 
losartan/amlodipine combination is also a good option for hypertensive 
patients with diabetes or metabolic syndrome, in addition to other 
cardiovascular risk factors.
Conclusion
The bioequivalence of Losanet AM 100/10 losartan and amlodipine 
combination tablets (Test Product/Pharmaline s.a.l, Lebanon) and 
Cozaar® 100 mg losartan tablets (Reference Product/ MSD, UK) 
coadministered with Norvasc 10 mg amlodipine tablets (Reference 
Product/ Pfizer, Canada) following the administration of a single dose 
of 100 mg losartan and 10 mg amlodipine to healthy adults under fast 
conditions was demonstrated. Single dose of the FDC tablet or the 
individual monotherapies were generally well tolerated. Both the FDC 
tablet and the coadministration of individual tablets can be considered 
therapeutic equivalent, and thus they can be substituted for each 
other without any adjustment in dose or other additional therapeutic 
monitoring. The study provides support for administration of the FDC 
tablet as an alternative option to co-administration of the individual 
tablets with the added benefits of enhanced patient compliance and 
convenience.
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